Stockscreener 앱 받기
0.3102
8.76%
-0.0298
시간 외 거래:
.31
-0.0002
-0.06%
전일 마감가:
$0.34
열려 있는:
$0.3371
하루 거래량:
1.04M
Relative Volume:
0.15
시가총액:
$5.86M
수익:
$2.47M
순이익/손실:
$-24.73M
주가수익비율:
-0.0736
EPS:
-4.213
순현금흐름:
$-20.36M
1주 성능:
-11.27%
1개월 성능:
-56.63%
6개월 성능:
-92.35%
1년 성능:
-97.53%
1일 변동 폭
$0.3058
$0.3401
1주일 범위
$0.3058
$0.3609
52주 변동 폭
$0.3058
$14.80
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, NTRA, IQV, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.3102 | 6.43M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
609.82 | 223.02B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.14 | 140.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.93 | 47.01B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
261.77 | 42.35B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
146.93 | 40.35B | 7.23B | 1.41B | 1.09B | 4.979 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VOLITIONRX LTD SEC Filing (Sep 11, 2026) - Stock Titan
Lagoda Investment Management, L.P. Adds VolitionRX Ltd (VNRX) -- Shares Look 98% Undervalued on GF Value - GuruFocus
VNRX Looks 98.1% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
A blood-based method detected 95% of stage I and II cancers. - Stock Titan
Dilution risk flagged as VolitionRx (NYSE: VNRX) registers more Lind shares for resale - Stock Titan
VolitionRx (NYSE: VNRX) details Lind note and warrant stake under 4.99% cap - Stock Titan
Lagoda Investment Management Elevates VOLITIONRX LTD (AMEX: VNRX) Stake to Activist 13D Filing at 7.4% - Kalkine Media
VNRX - Finviz
Fatima Dickey Pushes for Changes at VolitionRx with 7.4% Stake - TradingView
$11M VolitionRx (VNRX) stake comes with call to cut executive pay - Stock Titan
VolitionRx Removes $10M Annual Cap on ATM Sales Via Lind Waiver - Minichart
$VolitionRX (VNRX.US)$ it be like that. not even tripping cuz! - Moomoo
VolitionRx Files for Secondary Offering of Common Shares - Moomoo
This $21 Stock Has CRAZY Potential Baby Sleep (NynJ4YJi1C) - mshale.com
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results - Sahm
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - Benzinga
$VolitionRX (VNRX.US)$ - Moomoo
VolitionRx revenue rises 112% in H1FY26; shares surge 100% - scanx.trade
VolitionRX Ltd (VNRX) (Q2 2026) Earnings Call Highlights: Strate - GuruFocus
Benchmark reiterates Hold on VolitionRX stock amid cost cuts - Investing.com
Benchmark reiterates Hold on VolitionRX stock amid cost cuts By Investing.com - Investing.com Canada
VNRX Looks 97.6% Undervalued on GF Value™ - GuruFocus
Lagoda Investment discloses 14.0% VolitionRX (VNRX) stake in amended Schedule 13G - Stock Titan
Teleconferência de Resultados do 2º Trimestre de 2026 da VolitionRx (VNRX): Custos Caem à Medida que o Pipeline Nu.Q Avança - TradingKey
Conferencia de resultados del Q2 de 2026 de VolitionRx (VNRX): los costos caen a medida que avanza la cartera de desarrollo de Nu.Q - TradingKey
VolitionRx (VNRX) Q2 2026 Ergebniskonferenz: Kosten sinken bei Fortschritten der Nu.Q-Pipeline - TradingKey
Volitionrx Ltd earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Transcript : VolitionRx Limited, Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip - Investing.com Canada
VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
VolitionRx Limited Q2 2026 Earnings Call Summary - Yahoo Finance
VolitionRx Q2 Revenue Flat, but Licensing Talks and $5M Milestone Ahead - Minichart
VolitionRx targets $3.8B sepsis market with Nu.Q NETs platform - scanx.trade
VolitionRX: Q2 Earnings Snapshot - marketscreener.com
VolitionRx Q2 2026: Operating expenses fall 32% to $4.6 million - scanx.trade
Form 8K Volitionrx Ltd For: 13 August By Investing.com - Investing.com Nigeria
Form 8K Volitionrx Ltd For: 13 August - Investing.com India
VolitionRx (VNRX) flags going concern risk amid $14M loss and NYSE plan - Stock Titan
VolitionRx Limited (NYSE: VNRX) doubles H1 2026 revenue and trims losses - Stock Titan
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside - Yahoo Finance
VolitionRX Ltd (VNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VolitionRx tests finger-prick sepsis prototype in patients - Investing.com Nigeria
VolitionRx tests finger-prick sepsis prototype in patients By Investing.com - Investing.com Australia
VolitionRx Limited Demonstrates Utility of Rapid Point-Of-Care Finger-Prick Test in Sepsis Patients - marketscreener.com
VolitionRx lateral flow test correlates with legacy assay in sepsis patients - scanx.trade
VolitionRx call will cover Q2 results and upcoming milestones - Stock Titan
VolitionRx to discuss Q2 2026 results and busin... - Pluang
5 Stocks To BUY HEAVY In Early August 2026 Cat Deeley (ii210v0TXj) - Mshale
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.01%
0.36%
자본화:
|
볼륨(24시간):